TL;DR: Nara Organics recalled all lots of its powdered infant formula on June 13, 2026, after federal officials linked three infant botulism hospitalizations to the product.

WASHINGTON — Nara Organics of New York, NY, is voluntarily recalling all lots of Nara Organics Powdered Infant Formula currently on the market because of a potential risk of Clostridium botulinum contamination, according to the U.S. Food and Drug Administration posting titled NARA ORGANICS RECALLS ALL LOTS OF NARA INFANT FORMULA BECAUSE OF POSSIBLE HEALTH RISK.

The Company Announcement Date was June 13, 2026, and the FDA Publish Date was June 13, 2026. The Reason for Announcement was listed as potential risk of Clostridium botulinum contamination. The Product Type was listed as Food & Beverages. The Brand Name was listed as Nara Organics. The Product Description was listed as Whole Milk Powdered Infant Formula.

The Food and Drug Administration and Centers for Disease Control and Prevention contacted Nara Organics late Friday, June 12, 2026, and provided information about 3 cases of infant botulism in infants who the CDC reported had consumed Nara formula. The 3 infants were hospitalized and treated with BabyBIG (Botulism Immune Globulin Intravenous) in California, Washington, and Pennsylvania. There are no reported deaths.

What FDA and CDC reported on June 12-13

The three specific product lots these infants were exposed to are 709125280E14F2, 709125288E14F2, and 708125174E14F2, according to the company announcement posted by FDA. To date, Nara infant formula has not tested positive for C. botulinum. However, Nara is voluntarily recalling all products currently in market.

Nara said it is working closely with the FDA, Centers for Disease Control and Prevention, and state partners to support their investigation into the root causes of these cases. The company described its action as out of an abundance of caution and said it is taking aggressive action to ensure the safety of babies and families who use the product.

Nara Organics Powdered Infant Formula was distributed nationally across Target retail stores, Target.com, and Nara.com between July 2025 and June 2026. Nara Infant Formula is not distributed outside of the USA.

Customers should stop using the affected products immediately. If a baby has consumed this product and is presenting symptoms of infant botulism, the announcement says to contact a healthcare provider for immediate care.

How to identify the recalled infant formula

Affected Product Details listed in the FDA posting include two sizes. Nara Organics Whole Milk Infant Formula, 700g, carries UPC 860013251901. Nara Organics Whole Milk Infant Formula, 400g, carries UPC 860013251918.

All lots currently on the market are included in this voluntary recall. The lot code can be found on the bottom of each can.

The specific codes listed are 408125075E14F2, 708125076E14F2, 708125083E14F2, 408125139E14F2, 708125141E14F2, 708125145E14F2, 708125174E14F2, 709125273E14F2, 709125280E14F2, 709125288E14F2, 409125307E14F2, 70926019ENNB, 70926029ENNB, 70926035ENNB, 70926039ENNB, and 70926042ENNB.

Product photos were made available through the FDA recall page. The FDA notes that when a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service and does not endorse either the product or the company.

Consumers listed for contact are [email protected]. Media contact is listed as [email protected]. Customers with questions are encouraged to visit Nara's website or email [email protected].

What parents should do now

The announcement lists symptoms to watch for. Infant botulism is described as a rare but potentially fatal illness that presents a serious threat to the health of infants which occurs when Clostridium botulinum spores are ingested and colonize the intestinal tract, producing botulinum neurotoxins in the immature gut of infants.

Affected infants can present with some or all of the following signs and symptoms: constipation, poor feeding, ptosis (drooping eyelid), sluggish pupils, low muscle tone, difficulty sucking and swallowing, weak or altered cry, generalized weakness, respiratory difficulty, and possibly respiratory arrest.

The consumer instructions also list symptoms including, but not limited to vomiting, diarrhea, constipation, poor feeding, drooping eyelids, and weak crying. Parents observing those signs after use are told to seek immediate care.

To report an illness or adverse event, consumers can report a Product Problem through SmartHub, complete an electronic Voluntary MedWatch form online, or complete a paper Voluntary MedWatch form that can be mailed to FDA.

Refunds for Target and direct buyers

Nara will automatically refund all consumers who purchased formula from its website in May and June 2026. Other customers with unused product may request a refund by taking a photo of the bottom of each can and completing the refund form at https://nara.com/pages/refund-request-form.

Target customers may return their product to Target retail locations or follow Target's online return instructions. The general FDA contact number listed on the recall page is 1-888-INFO-FDA (1-888-463-6332).

Moringa capsules expanded for Salmonella risk

In a separate action posted June 11, 2026, Total Nutrition Inc. of Deer Park, NY, voluntarily expanded its recall of TNVitamins and Doctor's Pride Ultra Potent Complete Green Superfood Moringa Capsules due to the potential to be contaminated with Salmonella, according to the FDA posting titled Total Nutrition Inc. Expands Recall of TNVitamins and Doctor's Pride Ultra Potent Complete Green Superfood Moringa Capsules Because of Possible Health Risk Following Further Supply Chain Review.

The Company Announcement Date was June 11, 2026, and the FDA Publish Date was June 11, 2026. The Reason for Announcement was Possible Salmonella Contamination. The Product Type included Food & Beverages and Foodborne Illness. The Brand Names were TNVitamins and Doctor's Pride.

The recalled product was distributed nationally through the online platforms Amazon, Walmart, TikTok Shop, Target, and the company's websites http://www.tnvitamins.com/ and https://www.doctorspride.com/. The product is packaged in white HDPE supplement bottles with smooth, white caps and 120 clear capsules filled with green moringa powder.

Affected lots include TNVitamins Ultra Potent Complete Green Superfood Moringa 10,000 mg (120 capsules) Lot 2507199 Exp. 09/2027, Lot 2512-304 Exp. 02/2028, Lot 2793 Exp. 02/2028, Lot 2748 Exp 07/2027, Lot 2725 Exp. 04/2027 (newly added), and Lot 2503104 Exp. 04/2027 (newly added). Doctor's Pride Complete Green Superfood Ultra Potent Moringa 10,000 mg (120 capsules) includes Lot 2507199 Exp. 09/2027, Lot 2748 Exp. 07/2027, and Lot 2725 Exp. 04/2027 (newly added).

The recall was initiated following notification from the FDA and CDC that these products may be implicated in an ongoing investigation associated with moringa-containing dietary supplement products. The company said this expansion follows an ongoing supply chain investigation that identified additional lot numbers linked to the same raw material lot that prompted the original recall.

The expansion was discovered during a supply chain traceability review which identified a common raw material from Lot 2507199 or 2512-304, one of the original recalled lots. Total Nutrition Inc. has ceased distribution and sale of the identified product and has initiated removal orders across all applicable sales and fulfillment channels while the FDA, CDC and the company continue their investigation.

Salmonella is described in that announcement as an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis, and arthritis.

Soft cheese recalled for Listeria risk

On June 9, 2026, FDA published a recall from Clover Hill Dairy of Mechanicsville, Maryland, voluntarily recalling all Soft Ricotta/Requeson Cheese because it has the potential to be contaminated with Listeria monocytogenes, according to the FDA posting titled Clover Hill Dairy Recalls Soft Ricotta/Requeson Cheese Due to Possible Health Risk.

The Company Announcement Date was June 09, 2026, and the FDA Publish Date was June 09, 2026. The Product Type included Food & Beverages and Foodborne Illness. The Reason for Announcement was potential to be contaminated with Listeria monocytogenes. The Company Name was Clover Hill Dairy, LLC. The Brand Name was Clover Hill Dairy.

Clover Hill Soft Ricotta/Requeson cheese was distributed from May 4th, 2026 through May 30th, 2026 in North Carolina, New York, Virginia, Maryland, New Jersey and Washington, DC through bulk distributors, retail stores and directly to consumers.

The cheese was sold in retail size packaging as ten (10), twelve (12) and fourteen (14) ounce individually packaged clamshell containers. For clamshell containers with the Clover Hill Dairy Cheese brand name, the announcement says to look for Clover Hill Dairy's plant number 24-128 on the product label to assist with identifying recalled product.

The recalled cheese was also sold in bulk five (5) gallon and two (2) gallon buckets to some customers that repackaged the cheese. The announcement says the bulk cheese may be repackaged under individual bulk distributor brand names including but not limited to KESSO, QUESOS LA RICURA, IZALCO, DE MI PUEBLO, and RIO LINDO.

To the best of the company's knowledge, to date, eight (8) cases of Listeria infections may have been linked to Clover Hill Soft Ricotta/Requeson cheese as published by the FDA in cooperation with the Maryland Department of Health (MDH). Clover Hill Dairy was made aware of the potential public food health risk by the MDH.

Clover Hill Dairy has ceased production and distribution of all cheese products and has initiated a voluntary recall for Clover Hill Dairy Soft Ricotta/Requeson while the FDA, MDH and Clover Hill Dairy continue their investigations. Consumers who purchased recalled cheese are urged to return it to the place of purchase in its original packaging for a full refund. Consumers with questions may contact Southern Maryland Agricultural Development Commission on behalf of Clover Hill Dairy at 240-528-8850 extension 327.

Listeria monocytogenes is described in that announcement as an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, or others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain, and diarrhea, Listeria infection can cause miscarriages and still births among pregnant women.

FDA tests faster tracing for high-risk foods

Amid the recalls, the FDA on June 10, 2026 released a report on a series of traceability readiness tabletop exercises held with industry between March 9 and April 1, 2026, according to the FDA constituent update titled FDA Releases Report on Traceability Readiness Tabletop Exercises and Updated FAQS.

The exercises were designed to help the food industry prepare to comply with the Food Traceability Rule (FTR). The FTR — established under Section 204 of the FDA Food Safety Modernization Act — requires covered entities that manufacture, process, pack, or hold foods on the FDA Food Traceability List to maintain additional records that allow FDA to more rapidly and accurately trace food through the supply chain.

As part of the tabletop exercises, the FDA worked with industry participants to simulate an FTR records request from FDA. The exercises tested whether participants could locate traceability records associated with the handling of a specific product during a short, defined date range, and provide the information from those records in an electronic sortable spreadsheet within 24 hours, which is consistent with the requirements of the FTR.

The exercises demonstrated that meaningful progress is being made toward meeting the FTR requirements. Most firms responded within 24 hours, and proactive supply chain coordination — more than any particular technology — drove the strongest results. The agency characterized the results as encouraging overall, even though the exercises also demonstrated that some challenges remain with certain data elements.

The FDA said it will use the findings to inform its ongoing outreach, education, and technical assistance efforts. These exercises, coupled with ongoing engagements, will also help inform potential flexibilities regarding the lot-level tracking requirements in the FTR. The agency recently issued a discussion paper on this topic and said it looks forward to hearing more from interested stakeholders at the public meeting on June 15th and through feedback that can be submitted to a docket as described in the discussion paper.

Additionally, to further support implementation, the FDA has updated its frequently asked questions on the FTR to provide greater clarity on topics including the Traceability Lot Code source reference, food traceability plans, and intracompany shipments. The tabletop exercises fulfilled a Congressional directive under the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37).

Sources referenced